stockrow
Friday 6 November 2026
Export DMAC’s income statement to Excel — free account
DiaMedica Therapeutics, Inc.
DMAC Healthcare Biotechnology
- EPS
- −5.56%
- Free cash flow
- −6.75%
- Total debt
- −90.0%
Quarter to June 2026, against a year earlier
9.46
0.42
+4.65%
Follow DMAC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 1 | — | — | — | — | — | — | — | — | — | 10 | 10 | 10 | 0.0% | |
| Gross margin, % | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (2) | (4) | (6) | (11) | (12) | (14) | (14) | (19) | (24) | (33) | (38) | +35.0% | ||||||
| EBT margin, % | 0.00 | 0.00 | (1,130.80) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (2) | (4) | (6) | (11) | (12) | (14) | (14) | (19) | (24) | (33) | (38) | +34.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.47) | (0.68) | (0.74) | (0.89) | (0.78) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) | (0.72) | +4.5% | ||||||
| Cash flow | (0.64) | (0.66) | (0.74) | (0.76) | (0.59) | (0.59) | (0.44) | (0.58) | (0.55) | (0.62) | (0.58) | (0.3%) | ||||||
| Capex | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (5.5%) | ||||||
| Free cash flow | (0.64) | (0.66) | (0.74) | (0.76) | (0.59) | (0.59) | (0.44) | (0.58) | (0.55) | (0.62) | (0.59) | (0.4%) | ||||||
| Book value | 0.26 | 0.13 | 2.20 | 0.64 | 1.66 | 2.12 | 1.20 | 1.57 | 1.01 | 1.19 | 0.71 | +18.3% | ||||||
| Shares, m | 5 | 6 | 8 | 12 | 16 | 21 | 26 | 33 | 40 | 47 | 51 | +29.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | 0.00 | — | — | — | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | 1.32 | — | — | — | — | — | — | — | 13.30 | — | ||||||
| EV/Sales | — | — | 0.00 | — | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | (1.00) | — | — | — | — | — | — | — | (14.78) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (4) | (6) | (9) | (9) | (12) | (12) | (19) | (22) | (29) | (32) | +28.6% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +21.6% | ||||||
| Free cash flow | (3) | (4) | (6) | (9) | (9) | (12) | (12) | (19) | (22) | (29) | (32) | +28.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | 0 | 17 | 8 | 26 | 44 | 32 | 51 | 39 | 55 | 38 | +52.7% | |||||
| Net debt | (2) | (1) | (17) | (8) | (27) | (45) | (33) | (53) | (44) | (60) | (44) | +48.2% | ||||||
| Shareholders’ equity | 1 | 1 | 17 | 8 | 26 | 44 | 32 | 51 | 41 | 56 | 38 | +52.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (212.13) | (231.84) | (56.94) | (77.75) | (66.18) | (36.91) | (34.21) | (43.77) | (48.64) | (60.84) | (98.18) | +151.3 pt | |||||
| ROIC | 0.00 | 0.00 | (1,920.74) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (33,683.33) | (416.63) | (64.34) | (86.43) | (73.10) | (38.81) | (36.06) | (46.77) | (53.27) | (67.68) | (114.62) | +33,615.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 7 | 9 | 9 | 9 | 11 | 15 | 16 | 19 | 28 | 35 | — | +19.6% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2018 · latest quarter Sep 2018
DiaMedica Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLBT SL SCIENCE HLDG | $504.7M | — | — | — | — | — | — | — | Compare |
| PBYI Puma Biotechnology, Inc. | $504.3M | 15.3× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| OVID Ovid Therapeutics | $503.9M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| CAPR Capricor Therapeutics, Inc. | $500.0M | — (loss-making) | — (loss-making) | −7.92% (below 0%: shrinking) | n/m | −72.88% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| DMAC DiaMedica Therapeutics, Inc. | $487.5M | — (loss-making) | — (loss-making) | — | n/m | −6.75% (below 0%: shrinking) | 0.00% | 0.00% | |
| RGNX REGENXBIO Inc. | $487.2M | — (loss-making) | — (loss-making) | −69.19% (below 0%: shrinking) | n/m | +168.05% (above 0%: growing) | 87.55% | (387.84%) | Compare |
| INDP Indaptus Therapeutics, Inc. | $485.3M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CBIO Crescent Biopharma, Inc. | $480.6M | — (loss-making) | — (loss-making) | +1,038,900.00% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $478.6M | — (loss-making) | — (loss-making) | −45.23% (below 0%: shrinking) | n/m | −87.21% (below 0%: shrinking) | 79.80% | (18.79%) | Compare |
| Median of peers | $493.6M | — | — | −0.09% | — | −72.88% | 87.55% | 0.00% |
Pay and ownership Proxy statement filed 1 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.73m | 5.28m | 504.00 |
| 2024 | 1.55m | 2.44m | 344.00 |
| 2023 | 1.22m | 1.42m | 180.00 |
Ownership
Directors and executive officers, together
5.00%
Trill AB Sveavägen
16.40%
TomEqt Private AB c/o KinKon AB, Biblioteksgatan
15.58%
Richard Jacinto II
9.20%
Leon G. Cooperman St. Andrews Country Club,
6.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement